Fig. 2

Membranous PSMA expression of BML is heterogeneous in clinical samples obtained from patients with mCRPC. (A) Membranous PSMA expression in mCRPC status. Expression of membranous PSMA quantified by H-score and presented in order of increasing MHscore. Degree of heterogeneity in mPSMA was measured by SDI and depicted as heat map ranging from low heterogeneity (light green) to high heterogeneity (dark green). PSMA-negative cases are indicated with a dashed line in the plot with the definition as MHscore ≤ 20. (B) Box plot of PSMA MHscore distribution across bone metastatic sites, with no significant difference was observed. (C) Head-to-head comparison bar plots showing the expression profiles of other well-established TAAs in PSMA-negative mCRPC cases. (D) Box plot showing the comparison of MHscore for well-established TAAs in PSMA-negative mCRPC cases. Significant differences across subgroups are marked in the plot, *represents p < 0.05, **represents p < 0.01, ***represents p < 0.001. (E) Heatmap of NMR classification across TAAs in PSMA-negative mCRPC cases. NMR > 50% indicates a membranous dominant expression pattern, while NMR < 50% indicates a cytoplasmic dominant expression pattern.